AbbVie Inc. Financing cash flow

Financing cash flow of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Financing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Financing cash flow for the quarter ending December 30, 2020 was $-3.7 Billion (a 31.31% increase compared to previous quarter)
  • Year-over-year quarterly Financing cash flow increased by 52.56%
  • Annual Financing cash flow for 2020 was $-11.5 Billion (a -161.48% decrease from previous year)
  • Annual Financing cash flow for 2019 was $18.7 Billion (a -229.95% decrease from previous year)
  • Annual Financing cash flow for 2018 was $-14.4 Billion (a 161.18% increase from previous year)
  • Twelve month Financing cash flow ending December 30, 2020 was $-11.5 Billion (a -161.19% decrease compared to previous quarter)
  • Twelve month trailing Financing cash flow decreased by -153.08% year-over-year
Trailing Financing cash flow for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-11.5 Billion $18.8 Billion $21.2 Billion $21.7 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Financing cash flow of AbbVie Inc.

Most recent Financing cash flowof ABBV including historical data for past 10 years.

Interactive Chart of Financing cash flow of AbbVie Inc.

AbbVie Inc. Financing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3,695.0 $-2,814.0 $-2,570.0 $-2,422.0 $-11,501.0
2019 $26,602.0 $-441.0 $-2,070.0 $-5,383.0 $18,708.0
2018 $-3,825.0 $916.0 $-8,978.0 $-2,509.0 $-14,396.0
2017 $-1,928.0 $-810.0 $-980.0 $-1,794.0 $-5,512.0
2016 $-2,502.0 $-1,371.0 $1,164.0 $-1,219.0 $-3,928.0
2015 $-2,431.0 $-1,056.0 $10,169.0 $-930.0 $5,752.0
2014 $-882.0 $-719.0 $-415.0 $-1,277.0 $-3,293.0
2013 $-747.0 $-613.0 $-500.0 $-1,582.0 $-3,442.0
2012 $2,389.0 $2,244.0 $-1,326.0 $-1,376.0 $1,931.0
2011 $-1,561.09 $-2,251.24 $-1,774.25 $-1,196.45 $-6,783.0
2010 $65.2 $65.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.